摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-Boc-4-氟-4-哌啶甲酸 | 614731-04-3

中文名称
1-Boc-4-氟-4-哌啶甲酸
中文别名
1-BOC-4-氟-4-哌啶羧酸
英文名称
1-(tert-butoxycarbonyl)-4-fluoropiperidine-4-carboxylic acid
英文别名
1-boc-4-fluoro-4-piperidinecarboxylic acid;4-fluoro-1-[(2-methylpropan-2-yl)oxycarbonyl]piperidine-4-carboxylic acid
1-Boc-4-氟-4-哌啶甲酸化学式
CAS
614731-04-3
化学式
C11H18FNO4
mdl
MFCD08062530
分子量
247.267
InChiKey
NRQOTEPIFSRDMH-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    346.3±42.0 °C(Predicted)
  • 密度:
    1.22±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.4
  • 重原子数:
    17
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.818
  • 拓扑面积:
    66.8
  • 氢给体数:
    1
  • 氢受体数:
    5

安全信息

  • 海关编码:
    2933399090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335

SDS

SDS:72e22873b34714f5bcc1959626e02e6e
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 1-Boc-4-fluoro-4-piperidinecarboxylic acid
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 1-Boc-4-fluoro-4-piperidinecarboxylic acid
CAS number: 614731-04-3

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C11H18FNO4
Molecular weight: 247.3

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    1-Boc-4-氟-4-哌啶甲酸硼烷四氢呋喃络合物 作用下, 以 四氢呋喃 为溶剂, 反应 5.0h, 以100%的产率得到1-叔丁氧羰基-4-氟-4-(羟甲基)哌啶
    参考文献:
    名称:
    N-(取代磺酰基)苯甲酰胺类衍生物及其制备方法和医药用途
    摘要:
    本发明涉及N‑(取代磺酰基)苯甲酰胺类衍生物及其制备方法和医药用途。具体而言,本发明涉及一种通式(I)所示的N‑(取代磺酰基)苯甲酰胺类衍生物、其制备方法及其可药用的盐,以及它们作为治疗剂,特别是作为Nav1.7抑制剂的用途,其中通式(I)中的各取代基的定义与说明书中的定义相同。
    公开号:
    CN109574927A
  • 作为产物:
    参考文献:
    名称:
    WO2008/98978
    摘要:
    公开号:
点击查看最新优质反应信息

文献信息

  • NEW HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES
    申请人:Ackermann Jean
    公开号:US20110065707A1
    公开(公告)日:2011-03-17
    The present invention relates to compounds of formula (I) as well as pharmaceutically acceptable salts thereof, wherein A 1 , A 2 , R 1 , R 2 , R 3 , R 4 , R 5 and R 6 have the significance given herein.
    本发明涉及式(I)的化合物以及其药学上可接受的盐,其中A1、A2、R1、R2、R3、R4、R5和R6具有本文中给出的含义。
  • [EN] HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES<br/>[FR] INHIBITEURS DE HSL UTILES DANS LE TRAITEMENT DU DIABÈTE
    申请人:HOFFMANN LA ROCHE
    公开号:WO2011029808A1
    公开(公告)日:2011-03-17
    Compounds of formula (I), as well as pharmaceutically acceptable salts thereof can be used in the form of pharmaceutical compositions, wherein A1, A2, R1,R2 R3,R4 R5 and R6 have the significance given in claim 1. Objects of the present invention are the compounds of formula (I) and their aforementioned salts and esters and their use as therapeutically active substances, a process for the manufacture of the said compounds, intermediates, pharmaceutical compositions, medicaments containing the said compounds, their pharmaceutically acceptable salts or esters, the use of the said compounds, salts or esters for the treatment or prophylaxis of illnesses, especially in the treatment or prophylaxis of diabetes, metabolic syndrome, dyslipidemia, atherosclerosis or obesity and the use of the said compounds, salts or esters for the production of medicaments for the treatment or prophylaxis of diabetes, metabolic syndrome, dyslipidemia, atherosclerosis or obesity.
    化合物的化学式(I),以及其药学上可接受的盐可以用作药物组合物的形式,其中A1,A2,R1,R2,R3,R4,R5和R6具有权利要求1中给定的含义。本发明的目的是化学式(I)的化合物及其上述的盐和酯,以及它们作为治疗活性物质的用途,制造所述化合物的方法,中间体,含有所述化合物的药物组合物,含有所述化合物、其药学上可接受的盐或酯的药物,所述化合物、盐或酯的用途用于治疗或预防疾病,特别是用于治疗或预防糖尿病、代谢综合征、血脂异常、动脉粥样硬化或肥胖症,以及所述化合物、盐或酯的用途用于生产用于治疗或预防糖尿病、代谢综合征、血脂异常、动脉粥样硬化或肥胖症的药物。
  • [EN] ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES D'ARYLMÉTHYLÈNE UTILISÉS EN TANT QUE BLOQUEURS DES CANAUX POTASSIQUES KV1.3 DE TYPE SHAKER
    申请人:DE SHAW RES LLC
    公开号:WO2021071806A1
    公开(公告)日:2021-04-15
    A compound of Formula (I) or a pharmaceutically acceptable salt thereof is described, wherein the substituents are as defined herein. Pharmaceutical compositions comprising the same and method of using the same are also described.
    描述了化合物的公式(I)或其药学上可接受的盐,其中取代基如本文所定义。还描述了包含相同化合物的药物组合物以及使用该药物的方法。
  • Nitrogen containing heterocyclic compounds and medicines containing the same
    申请人:——
    公开号:US20040167224A1
    公开(公告)日:2004-08-26
    Compounds represented by the following general formula: 1 (wherein X 1 , X 2 , X 3 and X 4 each independently represent a single bond, C 1-6 alkylene, etc.; A 2 represents optionally substituted phenyl, etc.; A 1 represents an optionally substituted 5- to 7-membered heterocyclic group containing —C(═Q 1 )— (wherein Q 1 represents oxygen, sulfur or ═N—R 11 (wherein R 11 represents hydrogen or C 1-6 alkyl)) and nitrogen, etc.; and Z 1 represents piperidin-diyl, etc.), salts thereof and hydrates of the foregoing.
    由以下一般式表示的化合物: 1 (其中X 1 、X 2 、X 3 和X 4 分别独立表示单键,C 1-6 烷基等;A 2 表示可选择地取代的苯基等;A 1 表示可选择地取代的含有—C(═Q 1 )—的5-至7-成员杂环基团(其中Q 1 表示氧、硫或═N—R 11 (其中R 11 表示氢或C 1-6 烷基))和氮等;以及Z 1 表示哌啶二基等),以及其盐和上述化合物的水合物。
  • [EN] SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF<br/>[FR] BENZAMIDES SUBSTITUÉS ET LEURS MÉTHODES D'UTILISATION
    申请人:GENENTECH INC
    公开号:WO2015078374A1
    公开(公告)日:2015-06-04
    The invention provides compounds having the general formula I, and pharmaceutically acceptable salts thereof, wherein the variables RA, RAA, subscript n, ring A, X2, L, subscript m, X1, R1, R2, R3, R4, R5, and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    这项发明提供了具有一般式I的化合物及其药用盐,其中变量RA、RAA、下标n、环A、X2、L、下标m、X1、R1、R2、R3、R4、R5和RN的含义如本文所述,并包含这种化合物的组合物和使用这种化合物和组合物的方法。
查看更多